A clinical trial update for somatropin recombinant was recorded on October 13, 2026. The study, registered as NCT06103513 and titled "Randomized Clinical Trial of Two Different Initial Growth Hormone Doses in Children," is a Phase 3 trial. According to ClinicalTrials.gov, the trial's current status is listed as recruiting.
The trial is designed to compare two different initial doses of growth hormone in a pediatric population, based on the study title. No results have been posted for this trial as of the date of this update. The information provided does not include details on enrollment numbers, specific dosing arms, or expected completion dates.
Somatropin recombinant remains classified as an unapproved research compound according to the regulatory status associated with this update. This trial update reflects only the recruitment status reported in the registry entry and does not indicate any outcome, safety finding, or efficacy conclusion. Readers should note that recruiting status means the trial is actively seeking participants and has not yet reported findings.
For more background on this compound, see the linked compound overview.